OceanBase Hosts Technical Symposium on Data x AI and Has Six Papers Accepted at ICDE 2025
In the symposium, Charlie Yang, Chief Technology Officer of OceanBase, presented OceanBase's vision for an AI-ready data infrastructure, emphasizing its commitment to empowering intelligent, scalable, and resilient data ecosystems. Notable professors, researchers and experts from The Chinese University of Hong Kong, The Hong Kong University of Science and Technology (Guangzhou), Northeastern University, and OneConnect Financial Technology (Hong Kong), shared their research findings and industry insights around data x AI innovations and applications.
Meanwhile, six papers authored or contributed to by the OceanBase team were accepted at ICDE 2025. Among them, " OceanBase Unionization: Building the Next Generation of Online Map Applications," co-authored with Alibaba and Cornell University researchers, was recognized as the Best Industry and Application Paper Runner Up. This paper proposes the architectural design of OceanBase's distributed database system, which "unitizes" services and operations into individual machines, bringing stronger disaster tolerance and achieving better performance in real-world testing with AMap, an online map application platform supporting large-scale distributed services.
Serving over 2,000 customers globally, including Alipay, Pop Mart, Trip.com, GCash and DANA, OceanBase remains dedicated to advancing database technologies in today's AI-driven era. Since 2024, more than ten of its research papers have been accepted at top database conferences worldwide, including ICDE, SIGMOD, and VLDB. These papers cover a wide range of topics in distributed database technology, such as innovative algorithm for solving the fair clustering problem, Paxos-backed Append-only Log File (PALF) system, and functionality-aware database tuning.
Since its inception in 2010, OceanBase has actively collaborated with esteemed universities and research institutes such as East China Normal University, Renmin University of China, Wuhan University, and Nanyang Technological University in Singapore, to explore the forefront of database technologies. These collaborations involve establishing joint laboratories, pursuing research projects, and co-hosting database competitions.
Moreover, OceanBase has partnered with institutions like Ant Research and the China Computer Federation to establish funds to conduct in-depth research on major technical challenges for modern databases, including "stand-alone and distributed integrated architecture," "transaction processing and analytical processing (TP and AP) integration," "storage-computing separation," and "database performance optimization", and bring scientific research into real-world applications.
About OceanBase
OceanBase is a distributed database launched in 2010. It provides strong data consistency, high availability, high performance, cost efficiency, elastic scalability, and compatibility with mainstream relational databases. It handles transactional, analytical, and AI workloads through a unified data engine, enabling mission-critical applications and real-time analytics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
34 minutes ago
- Korea Herald
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
SEOUL, South Korea, July 18, 2025 /PRNewswire/ -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension. It will be conducted as a multicenter, prospective, single-arm, open-label exploratory study. HyperQure™ is a next-generation laparoscopic RDN device developed over the past decade under the leadership of Professor Chang-Wook Jeong at Seoul National University Hospital. By adopting an extravascular approach, HyperQure™ addresses key limitations of conventional intravascular RDN, offering direct anatomical access to renal nerves with the potential for improved precision and outcomes. DeepQure is also conducting RDN clinical trials for resistant hypertension in both South Korea and the United States. Patient enrollment is nearing completion domestically, while trials are actively underway at five major academic medical centers across the U.S. The MFDS's approval for this new indication marks an important milestone, expanding HyperQure™'s potential from hypertension to atrial fibrillation and reinforcing its technical scalability and multi-disease therapeutic potential. HyperQure™ is ISO 13485–certified, GMP-compliant, and was designated as Innovative Medical Device No. 36 by the MFDS, underscoring its clinical relevance and breakthrough innovation. "This approval validates HyperQure™ as a next-generation solution that overcomes the limitations of traditional RDN techniques," said a DeepQure spokesperson. "With parallel trials in resistant hypertension and now atrial fibrillation, we are accelerating our push into the global cardiovascular market with a truly differentiated solution." About DeepQure DeepQure is a medical technology company pioneering minimally invasive therapies for cardiovascular and autonomic nervous system disorders. Founded by experts in clinical medicine, engineering, and global healthcare, the company is focused on developing breakthrough solutions that address unmet needs in cardiovascular diseases. DeepQure is headquartered in Seoul, South Korea, with clinical programs active in both Korea and the United States. About HyperQure™ RDN System HyperQure™ is DeepQure's proprietary laparoscopic renal denervation (RDN) system designed to treat conditions such as resistant hypertension and atrial fibrillation. Unlike conventional intravascular approaches, HyperQure™ utilizes an extravascular route to access and ablate renal nerves with enhanced precision. The system has been designated as an Innovative Medical Device by the Korean MFDS and has obtained ISO 13485 and GMP certifications, enabling global clinical deployment.
Korea Herald
35 minutes ago
- Korea Herald
Cohesity Gaia Integrates with Microsoft 365 Copilot to Simplify and Expand Access to Valuable Enterprise Data
Enables All Corporate Functions to Uncover Actionable Insights through AI-powered Search Across Stored Emails, Documents, Spreadsheets, and More SINGAPORE, July 18, 2025 /PRNewswire/ -- Cohesity, the leader in AI-powered data security, today announced the availability of its Cohesity Gaia integration with Microsoft 365 Copilot. The integration allows knowledge workers across an organization to tap into Cohesity backup data directly from the Microsoft 365 Copilot interface to gain insights and inform better business decisions. "Massive business insights lie dormant in organizations' backup data. Before Cohesity Gaia, it was virtually impossible to extract that data and use it to draw any actionable conclusions. Now that customers can mine this resource with ease, we believe these deeper insights will be transformational," said Gregory Statton, vice president of AI solutions, Cohesity. "By unifying Cohesity Gaia with a widely adopted tool like Microsoft 365 Copilot, we're helping customers make the most of their stored data, empowering use cases enterprise wide." A first-to-market innovation for unlocking the potential of backup data, Cohesity Gaia combines generative AI, large language models, and retrieval augmented generation techniques. As part of the integration with Microsoft 365 Copilot, users can simply enter conversational questions via their Microsoft 365 Copilot interface. Cohesity Gaia searches across vast amounts of backup data effortlessly, pinpoints critical information quickly, and surfaces actionable information for any department or job function. Granular, role-based access controls limit responses to align with user permissions, protecting sensitive data. "Generative AI has created a tipping point for enterprise AI deployments. The next phase of this journey will involve more AI-to-AI communications and expectations for transformative business outcomes," said Chantrelle Nielsen, group product manager, Microsoft 365 Copilot, Microsoft. "Microsoft 365 Copilot integration with Cohesity reflects this progression, giving enterprises more ways to take advantage of AI from the convenience of a single interface with a consistent user experience." "Cohesity and Microsoft continue to build on their partnership, working together to safeguard data and strengthen organizations' cyber resilience. This integration extends the value proposition even further to bring new benefits by instantly putting high-quality backup data at the fingertips of users across the enterprise," said Jared Crowley, senior director of Security & Software Partners, SHI International Corp. "The end result is faster, better decision making and fresh opportunities for maximizing customers' investments in Cohesity and Microsoft." Cohesity Gaia is a subscription-based service. Access to Cohesity Gaia capabilities within the Microsoft 365 Copilot is currently available at no additional cost for subscribers of both Cohesity Gaia and Microsoft 365 Copilot. For more on the integration and key benefits, visit the Cohesity blog and tune into the Cohesity Tech Insights podcast episode "Unlocking AI powered insights with Agents and Frontier Models." About Cohesity Cohesity is the leader in AI-powered data security. Over 13,600 enterprise customers, including over 85 of the Fortune 100 and nearly 70% of the Global 500, rely on Cohesity to strengthen their resilience while providing Gen AI insights into their vast amounts of data. Formed from the combination of Cohesity with Veritas' enterprise data protection business, the company's solutions secure and protect data on-premises, in the cloud, and at the edge. Backed by NVIDIA, IBM, HPE, Cisco, AWS, Google Cloud, and others, Cohesity is headquartered in Santa Clara, CA, with offices around the globe. To learn more, follow Cohesity on LinkedIn, X, and Facebook.
Korea Herald
14 hours ago
- Korea Herald
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
SEONGNAM, South Korea, July 17, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. The candidate incorporates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu' to enhance protective efficacy. SK bioscience previously utilized adjuvants in its COVID-19 vaccine, 'SKYCovione', and now seeks to expand this technology to influenza vaccines as part of its broader platform strategy. NBP607B contains an adjuvant developed by the Vaccine Formulation Institute (VFI), a Swiss-based non-profit vaccine research organization. Comprising multiple immune-boosting components, the adjuvant is expected to induce strong immune responses and antibody production in elderly individuals. SK bioscience has proactively conducted non-clinical studies since 2023 and reported promising results. The Phase 1/2 clinical trial is scheduled to begin during the upcoming Northern Hemisphere flu season, enrolling approximately 320 older adults in Korea and abroad. The study will evaluate the vaccine's immunogenicity and safety compared to an approved high-immunogenicity flu vaccine, with interim results expected by 2027. This marks the first attempt by a Korean company to submit an IND to develop a high-immunogenicity influenza vaccine using an adjuvant. If successful, the company plans to leverage the platform for other vaccines and establish a competitive edge in the global high-value vaccine market. The development aligns with global health authorities' increasing recommendations for enhanced flu vaccines in high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommends high-dose or adjuvanted influenza vaccines for adults aged 65 and older. The World Health Organization (WHO) also supports the use of adjuvanted vaccines for vulnerable populations. In Korea, the Korea Disease Control and Prevention Agency (KDCA) has indicated that domestically developed high-immunogenicity vaccines may be considered for inclusion in the National Immunization Program (NIP) if they meet appropriate criteria. According to market research firm Mordor Intelligence, the global vaccine market is projected to grow from USD 83.9 billion in 2025 to USD 114.8 billion in 2030, with an average annual growth rate of 6.5%. Demand for high-immunogenicity vaccines is expected to rise continuously due to global aging and the increasing number of immunocompromised individuals and those with chronic illnesses. SKYCellflu, SK bioscience's existing cell-based influenza vaccine, has already been recognized for its innovation. It became the world's first cell-based flu vaccine to receive prequalification (PQ) from the WHO and is currently approved in 11 countries, with supply through international procurement programs by United Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO). Jaeyong Ahn, CEO of SK bioscience, said, "We believe the combination of our proven SKYCellflu platform and our experience in adjuvanted vaccine development positions us well for success. We aim to establish a differentiated presence in the high-immunogenicity vaccine market while building a flexible platform for future infectious disease preparedness."
